Cargando…
A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer
The remarkable success of trastuzumab and other newly developed anti-HER2 (human epidermal growth factor receptor 2) therapies in breast, gastric, or gastroesophageal junction cancer patients has supported us to investigate the HER2 status and its possible therapeutic implication in mucinous epithel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602799/ https://www.ncbi.nlm.nih.gov/pubmed/25501060 http://dx.doi.org/10.1097/MD.0000000000000171 |
_version_ | 1782394794656399360 |
---|---|
author | Chen, Chi-Kuan Lee, Ming-Yung Lin, Wea-Lung Wang, Yu-Ting Han, Chih-Ping Yu, Cheng-Ping Chao, Wan-Ru |
author_facet | Chen, Chi-Kuan Lee, Ming-Yung Lin, Wea-Lung Wang, Yu-Ting Han, Chih-Ping Yu, Cheng-Ping Chao, Wan-Ru |
author_sort | Chen, Chi-Kuan |
collection | PubMed |
description | The remarkable success of trastuzumab and other newly developed anti-HER2 (human epidermal growth factor receptor 2) therapies in breast, gastric, or gastroesophageal junction cancer patients has supported us to investigate the HER2 status and its possible therapeutic implication in mucinous epithelial ovarian cancer (EOC). However, there is currently no standardization of HER2 scoring criteria in mucinous EOC. In this study, we aimed to compare both the assay performance characteristics of the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists scoring methods. Forty-nine tissue microarray samples of mucinous EOC from Asian women were analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) tests using the 2007 and the 2013 criteria, respectively. The overall concordance between IHC and FISH by the 2007 criteria was 97.92 % (kappa = 0.921), and that by the 2013 criteria was 100% (kappa = 1.000). The percentage of Her2 FISH-amplified cases showed an increasing trend significantly through their corresponding HER2 IHC ordinals by the 2007 and the 2013 criteria, respectively (P < 0.001, P < 0.001). After excluding equivocal cases, the specificity (100%) and positive predictive value (100%) were unchanged under either the 2007 or the 2013 criteria. The sensitivity (100%), negative predictive value (NPV) (100%), and accuracy (100%) of HER2 IHC were higher under the 2013 criteria than those (sensitivity 87.5%, NPV 97.6%, and accuracy 97.9%) under the 2007 criteria. Of the total 49 cases, the number (n = 4) of HER2 IHC equivocal results under the 2013 criteria was 4-fold higher than that (n = 1) under the 2007 criteria (8.16% vs 2.04%). Conclusively, if first tested by IHC, the 2013 criteria caused more equivocal HER2 IHC cases to be referred to Her2 FISH testing than the 2007 criteria. That decreased the false-negative rate of HER2 status and increased the detection rates of HER2 positivity in mucinous EOC. |
format | Online Article Text |
id | pubmed-4602799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-46027992015-10-27 A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer Chen, Chi-Kuan Lee, Ming-Yung Lin, Wea-Lung Wang, Yu-Ting Han, Chih-Ping Yu, Cheng-Ping Chao, Wan-Ru Medicine (Baltimore) 5700 The remarkable success of trastuzumab and other newly developed anti-HER2 (human epidermal growth factor receptor 2) therapies in breast, gastric, or gastroesophageal junction cancer patients has supported us to investigate the HER2 status and its possible therapeutic implication in mucinous epithelial ovarian cancer (EOC). However, there is currently no standardization of HER2 scoring criteria in mucinous EOC. In this study, we aimed to compare both the assay performance characteristics of the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists scoring methods. Forty-nine tissue microarray samples of mucinous EOC from Asian women were analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) tests using the 2007 and the 2013 criteria, respectively. The overall concordance between IHC and FISH by the 2007 criteria was 97.92 % (kappa = 0.921), and that by the 2013 criteria was 100% (kappa = 1.000). The percentage of Her2 FISH-amplified cases showed an increasing trend significantly through their corresponding HER2 IHC ordinals by the 2007 and the 2013 criteria, respectively (P < 0.001, P < 0.001). After excluding equivocal cases, the specificity (100%) and positive predictive value (100%) were unchanged under either the 2007 or the 2013 criteria. The sensitivity (100%), negative predictive value (NPV) (100%), and accuracy (100%) of HER2 IHC were higher under the 2013 criteria than those (sensitivity 87.5%, NPV 97.6%, and accuracy 97.9%) under the 2007 criteria. Of the total 49 cases, the number (n = 4) of HER2 IHC equivocal results under the 2013 criteria was 4-fold higher than that (n = 1) under the 2007 criteria (8.16% vs 2.04%). Conclusively, if first tested by IHC, the 2013 criteria caused more equivocal HER2 IHC cases to be referred to Her2 FISH testing than the 2007 criteria. That decreased the false-negative rate of HER2 status and increased the detection rates of HER2 positivity in mucinous EOC. Wolters Kluwer Health 2014-12-12 /pmc/articles/PMC4602799/ /pubmed/25501060 http://dx.doi.org/10.1097/MD.0000000000000171 Text en Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Chen, Chi-Kuan Lee, Ming-Yung Lin, Wea-Lung Wang, Yu-Ting Han, Chih-Ping Yu, Cheng-Ping Chao, Wan-Ru A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title | A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title_full | A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title_fullStr | A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title_full_unstemmed | A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title_short | A Qualitative Study Comparing the Assay Performance Characteristics Between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 Scoring Methods in Mucinous Epithelial Ovarian Cancer |
title_sort | qualitative study comparing the assay performance characteristics between the 2007 and the 2013 american society for clinical oncology and college of american pathologists her2 scoring methods in mucinous epithelial ovarian cancer |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602799/ https://www.ncbi.nlm.nih.gov/pubmed/25501060 http://dx.doi.org/10.1097/MD.0000000000000171 |
work_keys_str_mv | AT chenchikuan aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT leemingyung aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT linwealung aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT wangyuting aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT hanchihping aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT yuchengping aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT chaowanru aqualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT chenchikuan qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT leemingyung qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT linwealung qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT wangyuting qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT hanchihping qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT yuchengping qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer AT chaowanru qualitativestudycomparingtheassayperformancecharacteristicsbetweenthe2007andthe2013americansocietyforclinicaloncologyandcollegeofamericanpathologistsher2scoringmethodsinmucinousepithelialovariancancer |